TCT 130: Multiple Biomarkers to Predict Major Adverse Cardiovascular Events in Patients With Coronary Chronic Total Occlusions

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Grant Support/Research Contract - Canon, Siemens, NIH, Shockwave, Heartflow, Neovasc, Mercator
• Consultant Fee/Honoraria/Speaker's Bureau - Siemens, Philips, Intravascular Imaging Inc, DurVena, Mercator; Boston Scientific Corporation; Biotronik; Medtronic
• Equity/Stock(s)/Options - Intravascular Imaging Incorporated, DurVena
• Royalty/Intellectual Property Rights - Massachusetts General Hospital (owns IP)- right to receive Royalties from Canon, Terumo, Spectrawave